Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? - PubMed (original) (raw)

Review

Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?

Louis Harrison et al. Oncologist. 2004.

Free article

Abstract

Hypoxia is a common feature of solid tumors that occurs across a wide variety of malignancies. Hypoxia and anemia (which contributes to tumor hypoxia) can lead to ionizing radiation and chemotherapy resistance by depriving tumor cells of the oxygen essential for the cytotoxic activities of these agents. Hypoxia may also reduce tumor sensitivity to radiation therapy and chemotherapy through one or more indirect mechanisms that include proteomic and genomic changes. These effects, in turn, can lead to increased invasiveness and metastatic potential, loss of apoptosis, and chaotic angiogenesis, thereby further increasing treatment resistance. Investigations of the prognostic significance of pretreatment tumor oxygenation status have shown that hypoxia (oxygen tension [pO(2)] value < or =10 mmHg) is associated with lower overall and disease-free survival, greater recurrence, and less locoregional control in head and neck carcinoma, cervical carcinoma, and soft-tissue sarcoma. In view of the deleterious effect of hypoxia on standard cancer treatment, a variety of hypoxia- and anemia-targeted therapies have been studied in an effort to improve therapeutic effectiveness and patient outcomes. Early evidence from experimental and clinical studies suggests the administration of recombinant human erythropoietin (rHuEPO) may enhance the effectiveness of radiation therapy and chemotherapy by increasing hemoglobin levels and ameliorating anemia in patients with disease- or treatment-related anemia. However, further research is needed in the area of hypoxia-related treatment resistance and its reversal.

PubMed Disclaimer

Similar articles

• rHuEPO and improved treatment outcomes: potential modes of action.
  Blackwell K, Gascón P, Sigounas G, Jolliffe L. Blackwell K, et al. Oncologist. 2004;9 Suppl 5:41-7. doi: 10.1634/theoncologist.9-90005-41. Oncologist. 2004. PMID: 15591421 Review.
• rHuEPO and treatment outcomes: the preclinical experience.
  Ludwig H. Ludwig H. Oncologist. 2004;9 Suppl 5:48-54. doi: 10.1634/theoncologist.9-90005-48. Oncologist. 2004. PMID: 15591422
• Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
  Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM. Prosnitz RG, et al. Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1087-95. doi: 10.1016/j.ijrobp.2004.07.710. Int J Radiat Oncol Biol Phys. 2005. PMID: 15752888
• Impact of hemoglobin levels on tumor oxygenation: the higher, the better?
  Vaupel P, Mayer A, Höckel M. Vaupel P, et al. Strahlenther Onkol. 2006 Feb;182(2):63-71. doi: 10.1007/s00066-006-1543-7. Strahlenther Onkol. 2006. PMID: 16447012 Review.
• [Anemia impact on treatments of cervical carcinomas].
  Marchal C, Rangeard L, Brunaud C. Marchal C, et al. Cancer Radiother. 2005 Mar;9(2):87-95. doi: 10.1016/j.canrad.2005.01.004. Cancer Radiother. 2005. PMID: 15820436 Review. French.

Cited by

• High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases.
  Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A. Yan W, et al. Hepatology. 2012 Jun;55(6):1863-75. doi: 10.1002/hep.25572. Hepatology. 2012. PMID: 22234969 Free PMC article.
• 68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies.
  Verger E, Drion P, Meffre G, Bernard C, Duwez L, Lepareur N, Couturier O, Hindré F, Hustinx R, Lacoeuille F. Verger E, et al. PLoS One. 2016 Oct 14;11(10):e0164626. doi: 10.1371/journal.pone.0164626. eCollection 2016. PLoS One. 2016. PMID: 27741267 Free PMC article.
• Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma.
  Naghavi AO, Gonzalez RJ, Scott JG, Mullinax JE, Abuodeh YA, Kim Y, Binitie O, Ahmed KA, Bui MM, Saini AS, Zager JS, Biagioli MC, Letson D, Harrison LB, Fernandez DC. Naghavi AO, et al. Brachytherapy. 2016 Jul-Aug;15(4):495-503. doi: 10.1016/j.brachy.2016.03.013. Epub 2016 May 12. Brachytherapy. 2016. PMID: 27180128 Free PMC article.
• Evaluation of a hypoxia regulated gene panel in ovarian cancer.
  Baker AF, Malm SW, Pandey R, Laughren C, Cui H, Roe D, Chambers SK. Baker AF, et al. Cancer Microenviron. 2015 Apr;8(1):45-56. doi: 10.1007/s12307-015-0166-x. Epub 2015 May 22. Cancer Microenviron. 2015. PMID: 25998313 Free PMC article.
• Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure.
  van Laarhoven HW, Gambarota G, Lok J, Lammens M, Kamm YL, Wagener T, Punt CJ, van der Kogel AJ, Heerschap A. van Laarhoven HW, et al. Neoplasia. 2006 Jun;8(6):477-87. doi: 10.1593/neo.06115. Neoplasia. 2006. PMID: 16820094 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information